Raybow Biotech - B (6938.HK): Achieves Third Key Milestone in MASH R&D Collaboration with Boehringer Ingelheim

NewTimeSpace · 2026/05/06 08:00 · By Boyuan Chen

NewTimeSpace News: Suzhou Raybow Biotech Co., Ltd. (06938.HK) announced that it has achieved the third key milestone in its R&D collaboration with Boehringer Ingelheim (BI) for developing innovative therapeutic solutions for liver diseases (including Metabolic Dysfunction-Associated Steatohepatitis, MASH). MASH is a severe and progressive fatty liver disease affecting over 200 million people worldwide.

NewTimeSpace News: Suzhou Raybow Biotech Co., Ltd. (06938.HK) released a voluntary announcement on May 6, 2026, stating that it has reached the third key milestone in its R&D collaboration with Boehringer Ingelheim (BI). The collaboration focuses on developing innovative therapeutic solutions for liver diseases, with a specific focus on Metabolic Dysfunction-Associated Steatohepatitis (MASH).

MASH is a severe and progressive fatty liver disease that can lead to fibrosis, cirrhosis, liver failure, and liver cancer, impacting more than 200 million individuals globally.
Through this collaboration, the Company and BI aim to expand the future potential treatment options pipeline for MASH patients. The achievement of this milestone further strengthens the Company’s position as a strategic partner to global pharmaceutical companies and highlights the commercial potential of its siRNA platform.

As of the date of this announcement, the collaboration remains in the preclinical stage.

Tags：

Raybow Biotech-B 06938.HK BI R&D collaboration